Reference Detail

Ref Type

PMID

Authors

Ingo K. Mellinghoff, Katherine B. Peters, Timothy Francis Cloughesy, Howard A. Burris III, Elizabeth Anne Maher, Filip Janku, Gregory Michael Cote, Macarena Ines De La Fuente, Jennifer Leigh Clarke, Kha Le, Li Liu, Man Yuen, Marissa Arnofsky, Islam Hassan, Lori Steelman, Shuchi Sumant Pandya, Patrick Y. Wen

Title

Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.

Journal	Vol	Issue	Date	Pages	Journal Short Title

URL

https://meetinglibrary.asco.org/record/185066/abstract

Abstract Text

J Clin Oncol 38: 2020 (suppl; abstr 2504), DOI: 10.1200/JCO.2020.38.15_suppl.2504

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
IDH1 mutant	high grade glioma	predicted - sensitive	Vorasidenib	Phase I	Actionable	In a Phase I trial, Vorasidenib (AG-881) treatment resulted in an objective response in 13.6% (3/21, 1 partial response, 2 minor response) and stable disease in 77.3% (17/21) of patients with recurrent or progressive non-enhancing glioma harboring mutations in IDH1 (n=20) or IDH2 (n=1), with 60.5% of the patients remained progression-free and alive at 24 months (J Clin Oncol 38: 2020 (suppl; abstr 2504); NCT02481154).	detail...
IDH2 mutant	high grade glioma	predicted - sensitive	Vorasidenib	Case Reports/Case Series	Actionable	In a Phase I trial, Vorasidenib (AG-881) treatment resulted in an objective response in 13.6% (3/21, 1 partial response, 2 minor response) and stable disease in 77.3% (17/21) of patients with recurrent or progressive non-enhancing glioma harboring mutations in IDH1 (n=20) or IDH2 (n=1), with 60.5% of the patients remained progression-free and alive at 24 months (J Clin Oncol 38: 2020 (suppl; abstr 2504); NCT02481154).	detail...